Business Context and Reporting Period
Lantheus Holdings, Inc. (LNTH) filed this Form 8-K on June 19, 2020, to disclose the entry into a material definitive agreement. The filing addresses an amendment to the Credit Agreement of its wholly-owned subsidiary, Lantheus Medical Imaging, Inc. (LMI), necessitated by the impact of the COVID-19 pandemic and the near-term higher indebtedness resulting from the acquisition of Progenics Pharmaceuticals, Inc.
Key Financial Metrics and Covenant Changes
The filing details specific modifications to financial maintenance covenants and interest rates rather than reporting operational financial results for a specific period.
- Total Net Leverage Ratio: Waived through December 31, 2020. Future requirements are 5.50:1.00 (Q1 2021), 3.75:1.00 (Q2 2021), and 3.50:1.00 thereafter.
- Interest Coverage Ratio: Required to be at least 2.00:1.00 through Q1 2021, increasing to 3.00:1.00 thereafter.
- Consolidated Liquidity: A new covenant requires liquidity of no less than $150,000,000, tested on a continuing basis until the compliance certificate for Q1 2021 is delivered.
- Interest Rates (Interim): LIBOR plus 3.25% or Base Rate plus 2.25% until the Adjustment Date for Q1 2021.
- Commitment Fee (Interim): Set at 0.50% until the Adjustment Date for Q1 2021.
Material Changes Versus Prior Period
The primary material change is the relaxation of financial covenants to accommodate the company's current financial position. Specifically, the Total Net Leverage Ratio covenant has been temporarily waived, and a new Consolidated Liquidity floor of $150 million has been introduced. Interest rates and commitment fees have been temporarily increased compared to the post-adjustment terms, reflecting the higher risk profile during the interim period.
Outlook, Risks, and Management Commentary
Management attributes the amendment to the operational impacts of the COVID-19 pandemic and the decision not to immediately repay Progenics debt secured by Relistor royalties following the acquisition. The filing indicates a structured path to return to stricter leverage ratios (3.50:1.00) and lower interest spreads (LIBOR + 1.50% to 3.00%) starting in the fiscal quarter ending September 30, 2021, contingent on compliance with the Total Net Leverage Ratio.
Important Facts for Investor Verification
- Verify the company's current Consolidated Liquidity position to ensure it meets the new $150 million minimum threshold.
- Monitor the Total Net Leverage Ratio trajectory to ensure compliance with the 5.50:1.00 requirement for the fiscal quarter ending March 31, 2021.
- Assess the impact of the temporarily higher interest rates (LIBOR + 3.25%) on near-term cash flow and profitability.
- Review the status of the Progenics Pharmaceuticals acquisition and the associated Relistor royalty debt repayment timeline.